Logo image of MBIO

MUSTANG BIO INC (MBIO) Stock Fundamental Analysis

NASDAQ:MBIO - Nasdaq - US62818Q3020 - Common Stock - Currency: USD

1.24  +0.01 (+0.81%)

After market: 1.2888 +0.05 (+3.94%)

Fundamental Rating

1

Overall MBIO gets a fundamental rating of 1 out of 10. We evaluated MBIO against 568 industry peers in the Biotechnology industry. MBIO has a bad profitability rating. Also its financial health evaluation is rather negative. MBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MBIO had negative earnings in the past year.
In the past year MBIO has reported a negative cash flow from operations.
MBIO had negative earnings in each of the past 5 years.
In the past 5 years MBIO always reported negative operating cash flow.
MBIO Yearly Net Income VS EBIT VS OCF VS FCFMBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of MBIO (-169.23%) is worse than 86.27% of its industry peers.
Industry RankSector Rank
ROA -169.23%
ROE N/A
ROIC N/A
ROA(3y)-142.59%
ROA(5y)-109.12%
ROE(3y)-14059.8%
ROE(5y)-8466.01%
ROIC(3y)N/A
ROIC(5y)N/A
MBIO Yearly ROA, ROE, ROICMBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBIO Yearly Profit, Operating, Gross MarginsMBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, MBIO has less shares outstanding
The number of shares outstanding for MBIO has been reduced compared to 5 years ago.
MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBIO Yearly Shares OutstandingMBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
MBIO Yearly Total Debt VS Total AssetsMBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -64.45, we must say that MBIO is in the distress zone and has some risk of bankruptcy.
MBIO has a Altman-Z score of -64.45. This is amonst the worse of the industry: MBIO underperforms 94.72% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -64.45
ROIC/WACCN/A
WACCN/A
MBIO Yearly LT Debt VS Equity VS FCFMBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

MBIO has a Current Ratio of 0.68. This is a bad value and indicates that MBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
MBIO's Current ratio of 0.68 is on the low side compared to the rest of the industry. MBIO is outperformed by 91.73% of its industry peers.
A Quick Ratio of 0.68 indicates that MBIO may have some problems paying its short term obligations.
With a Quick ratio value of 0.68, MBIO is not doing good in the industry: 91.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.68
MBIO Yearly Current Assets VS Current LiabilitesMBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

MBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.82%, which is quite impressive.
EPS 1Y (TTM)43.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4312.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.94% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-392.25%
EPS Next 2Y-68.06%
EPS Next 3Y18.89%
EPS Next 5Y15.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBIO Yearly Revenue VS EstimatesMBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
MBIO Yearly EPS VS EstimatesMBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600 -800

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBIO Price Earnings VS Forward Price EarningsMBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBIO Per share dataMBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

MBIO's earnings are expected to grow with 18.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.06%
EPS Next 3Y18.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MUSTANG BIO INC

NASDAQ:MBIO (4/22/2025, 4:42:19 PM)

After market: 1.2888 +0.05 (+3.94%)

1.24

+0.01 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)05-13 2025-05-13
Inst Owners5.22%
Inst Owner Change-0.28%
Ins Owners0.19%
Ins Owner Change11.27%
Market Cap4.10M
Analysts82.86
Price TargetN/A
Short Float %5.49%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-147.62%
Min EPS beat(2)-365.07%
Max EPS beat(2)69.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.32
EYN/A
EPS(NY)-17.85
Fwd EYN/A
FCF(TTM)-14.97
FCFYN/A
OCF(TTM)-14.95
OCFYN/A
SpS0
BVpS-1.17
TBVpS-1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -169.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-142.59%
ROA(5y)-109.12%
ROE(3y)-14059.8%
ROE(5y)-8466.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.68
Altman-Z -64.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)95.65%
Cap/Depr(5y)117.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4312.79%
EPS Next Y-392.25%
EPS Next 2Y-68.06%
EPS Next 3Y18.89%
EPS Next 5Y15.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y75.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.96%
OCF growth 3YN/A
OCF growth 5YN/A